Announcements Trials
Browse Landscape

Phase

Phase 3 11Phase 2 3Phase 1 3Phase 1/2 2Phase 4 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 2Metastatic Castration-resistant Prostate Neoplasms 1

Interventions

Specimen Handling 107Biopsy 75Magnetic Resonance Spectroscopy 73pembrolizumab 56Cyclophosphamide 47fludarabine 40Nivolumab 25Carboplatin 24Cetuximab 22venetoclax 21Cisplatin 21Bevacizumab 20Radiotherapy 19atezolizumab 17X-Rays 17Ipilimumab 17fludarabine phosphate 16Fluorouracil 16Cytarabine 15Radiation 14Paclitaxel 14Leucovorin 14Irinotecan 14Gemcitabine 14durvalumab 12Temozolomide 12Pemetrexed 12CTLA-4 Antigen 12Azacitidine 12decitabine and cedazuridine drug combination 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × apalutamide × 30 days × Clear all
NCT03523442 2026-05-08

A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer

Janssen Research & Development, LLC

Phase 1 Active not recruiting
19 enrolled
Genitourinary

Prostatic Neoplasms

NCT04662580 2026-05-08

ARX517

Janssen Research & Development, LLC

Phase 1 Active not recruiting
183 enrolled
Genitourinary

Prostatic Neoplasms

NCT05818683 2026-05-08

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

Janssen Research & Development, LLC

Phase 1 Recruiting
300 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡